Literature DB >> 20165583

Cytoreductive nephrectomy: a treatment of the past.

Peter Venner1.   

Abstract

Year:  2010        PMID： 20165583      PMCID： PMC2812003          DOI： 10.5489/cuaj.779

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  8 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

Review 2.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; R S Witte; D L Trump
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

5.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Barbara A Murphy; Paul Russo; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

6.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

7.  A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.

Authors:  Mark Warren; Peter M Venner; Scott North; Tina Cheng; Chris Venner; Sunita Ghosh; Allison A Venner; Daygen Finch
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

8.  Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.

Authors:  S Mani; M B Todd; K Katz; W J Poo
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.